Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 979 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stability Clear all
Completed Phase 4 Interventional

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

NCT00672919
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
51
States / cities
Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 20, 2026, 4:28 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Gene Therapy for the Treatment of Chronic Stable Angina

NCT01002495
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
VM202
Biological
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
21 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 20, 2026, 4:28 AM EDT
Not listed Phase 4 Interventional

Safety of Amiodarone and Ranolazine Together in Patients With Angina

NCT01558830
View directory record Official record
Conditions
Chronic Stable Angina, Coronary Artery Disease, Atrial Fibrillation, Ventricular Tachycardia
Interventions
ranolazine, placebo
Drug
Lead sponsor
Cardiovascular Consultants of Nevada
Other
Eligibility
35 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Henderson, Nevada • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Oct 20, 2026, 4:28 AM EDT
Withdrawn Not applicable Interventional

Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression

NCT01770600
View directory record Official record
Conditions
Impulsivity, Active Suicidal Ideation, Depression
Interventions
placebo, Riperidone
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 20, 2026, 4:28 AM EDT
Terminated Phase 1 Interventional

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

NCT03866239
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Obinutuzumab, Atezolizumab, Cibisatamab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Los Angeles, California • Santa Monica, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 20, 2026, 4:28 AM EDT
Terminated Phase 1 Interventional

Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

NCT04044430
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer, Stage III Colorectal Cancer, Stage III Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Colorectal Cancer, Stage IIIC Rectal Cancer, Stage IV Colon Cancer, Stage IV Colorectal Cancer, Stage IV Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Colorectal Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Colorectal Cancer, Stage IVB Rectal Cancer, Stage IVC Colon Cancer, Stage IVC Colorectal Cancer, Stage IVC Rectal Cancer
Interventions
Binimetinib, Encorafenib, Nivolumab, Questionnaire Administration
Drug · Biological · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 20, 2026, 4:28 AM EDT
Recruiting Not applicable Interventional

The Effect of Mindfulness on Vascular Inflammation in Stable Coronary Disease

NCT04505865
View directory record Official record
Conditions
Atherosclerosis, Stress, Inflammation
Interventions
Stress Reduction
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 20, 2026, 4:28 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine

NCT00002312
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 4:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

NCT02748694
View directory record Official record
Conditions
Healthy Volunteers, Schizophrenia
Interventions
TAK-041, TAK-041 Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 20, 2026, 4:28 AM EDT
Terminated Phase 1 Interventional

Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer

NCT03189030
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
pLADD
Biological
Lead sponsor
Aduro Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 20, 2026, 4:28 AM EDT
Active, not recruiting Phase 2 Interventional

CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen

NCT06699836
View directory record Official record
Conditions
Metastatic Colorectal Cancer (mCRC)
Interventions
350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Irvine, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 20, 2026, 4:28 AM EDT
Recruiting No phase listed Observational

Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence

NCT05972070
View directory record Official record
Conditions
Myocardial Infarction, Percutaneous Transluminal Coronary Angioplasty, Coronary Artery Bypass, Stable Angina, Heart Failure, Valve Disease, Heart, Cardiac Rehabilitation, Stent
Interventions
ROMTech Portable Connect
Device
Lead sponsor
ROM Technologies, INC
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Brookfield, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 20, 2026, 4:28 AM EDT
Withdrawn No phase listed Observational

Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding

NCT00216983
View directory record Official record
Conditions
Burns
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 20, 2026, 4:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ocular Surface Microbiome

NCT02298881
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 20, 2026, 4:28 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

NCT07565428
View directory record Official record
Conditions
Negative Symptoms of Schizophrenia
Interventions
Roluperidone, risperidone, aripiprazole, olanzapine, Placebo
Drug
Lead sponsor
Minerva Neurosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Bellflower, California • Culver City, California • Garden Grove, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 20, 2026, 4:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Working to Increase Stability Through Exercise

NCT02714257
View directory record Official record
Conditions
Fractures, Bone, Serious Fall-related Injuries
Interventions
Enhanced Usual Care plus Exercise Coaching
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
65 Years and older
Enrollment
1,139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 20, 2026, 4:28 AM EDT
Recruiting Not applicable Interventional

The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants

NCT05223192
View directory record Official record
Conditions
Prematurity
Interventions
Music Therapy Entrainment with Ocean Disc Intervention
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
24 Weeks to 37 Weeks
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 20, 2026, 4:28 AM EDT
Completed Not applicable Interventional

The PCI Choice Trial: a Pilot Randomized Trial of a Decision Aid for Patients With Stable Coronary Artery Disease

NCT01771536
View directory record Official record
Conditions
Stable Angina
Interventions
Decision Aid
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 20, 2026, 4:28 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil

NCT01406145
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ASP0777, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
San Diego, California • Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 20, 2026, 4:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Promoting Healthy Weight With 'Stability Skills First'

NCT00626457
View directory record Official record
Conditions
Obesity
Interventions
Behavioral weight-loss/lifestyle interventions
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older · Female only
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Stanford, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 20, 2026, 4:28 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

NCT02000700
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 50 mg, Canagliflozin 300 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
10 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 20, 2026, 4:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Study of Peripheral Capillary Oxygen Saturation (SpO2): Vital Signs Patch (VSP)

NCT01899911
View directory record Official record
Conditions
Desaturation of Blood
Interventions
Vital Signs Patch (VSP)
Device
Lead sponsor
LifeWatch Services, Inc.
Industry
Eligibility
23 Years to 33 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2015 · Synced Oct 20, 2026, 4:28 AM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens

NCT00001091
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Months to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 4:28 AM EDT
Not listed No phase listed Observational

Immunologic Control of Drug Resistant HIV

NCT00053404
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2008 · Synced Oct 20, 2026, 4:28 AM EDT